Back to top
more

Apricus Biosciences, Inc (APRI)

(Delayed Data from NSDQ)

$0.22 USD

0.22
1,204,635

0.00 (0.00%)

Updated Jan 23, 2019 03:57 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Seelos Therapeutics, Inc. [APRI]

Reports for Purchase

Showing records 1 - 20 ( 96 total )

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 1

12/14/2018

Company Report

Pages: 5

Terminating coverage due to resource reallocation.

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 2

10/23/2018

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for APRI

Provider: ValuEngine, Inc

Price: 25.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 3

03/02/2018

Company Report

Pages: 5

2017 Financial Results Reported; FDA Meeting Expected Next Month; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 4

02/16/2018

Company Report

Pages: 5

Vitaros Complete Response Letter Received; Downgrade to Neutral with $1 Price Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 5

01/16/2018

Company Report

Pages: 6

Vitaros PDUFA Date One Month Away; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 6

11/07/2017

Company Report

Pages: 7

Maintain price target of $4.30

Provider: SEETHRUEQUITY, LLC

Analyst: TANDON A

Price: 25.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 7

11/03/2017

Company Report

Pages: 5

3Q17 Results Reported; Vitaros NDA Review on Track; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 8

10/03/2017

Company Report

Pages: 8

We are updating our price target for Apricus to $4.30

Provider: SEETHRUEQUITY, LLC

Analyst: TANDON A

Price: 25.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 9

09/05/2017

Company Report

Pages: 5

Vitaros PDUFA Date Set for February 17, 2018; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 10

08/30/2017

Company Report

Pages: 5

Vitaros NDA Resubmitted; Potential PDUFA in 1Q18; Reiterate Buy and Increasing Price Target to $4.50

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 11

08/03/2017

Company Report

Pages: 5

Vitaros NDA to Be Resubmitted in the Current Quarter; 2Q17 Financial Results; Reiterate Buy

Provider: Rodman & Renshaw, Co.

Price: 10.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 12

08/03/2017

Company Report

Pages: 5

Vitaros NDA to Be Resubmitted in the Current Quarter; 2Q17 Financial Results; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 13

05/12/2017

Company Report

Pages: 5

Vitaros NDA Resubmission On Track in 3Q17; 1Q17 Financial Results; Reiterate Buy

Provider: Rodman & Renshaw, Co.

Price: 10.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 14

05/12/2017

Company Report

Pages: 5

Vitaros NDA Resubmission On Track in 3Q17; 1Q17 Financial Results; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 15

04/26/2017

Company Report

Pages: 24

Restoring Vim and Vigor With Vitaros; Initiating Coverage at Buy and $4 Price Target

Provider: Rodman & Renshaw, Co.

Price: 75.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 16

04/26/2017

Company Report

Pages: 24

Restoring Vim and Vigor With Vitaros; Initiating Coverage at Buy and $4 Price Target

Provider: H.C. Wainwright & Co., Inc.

Price: 75.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 17

03/23/2017

Company Report

Pages: 4

Coverage dropped due to discontinuance of research services.

Provider: Taglich Brothers, Inc.

Analyst: NOBILE J

Price: 10.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 18

02/03/2017

Company Report

Pages: 4

We are dropping coverage of APRI shares to reallocate our research resources

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 19

11/17/2016

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 20

11/17/2016

Company Report

Pages: 8

3Q16 Recap - FDA Meeting the Catalyst

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party
// eof